pyridoxine has been researched along with Breast Cancer in 25 studies
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source
vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pyridoxine, an activated form of vitamin B6 used to treat allergic dermatitis, may prevent capecitabine-associated hand-foot syndrome (HFS), although evidence of the benefit of prophylactic pyridoxine is lacking." | 9.27 | A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer. ( Hattori, M; Hayashi, T; Iwata, H; Kobayashi, N; Nakada, T; Saito, K; Sawaki, M; Toyama, T; Tsuneizumi, M; Yokota, I; Yoshimura, A, 2018) |
| " The objective of this study was to determine the associations between folate, cobalamin, and pyridoxine with fasting plasma tHcy concentration in breast cancer (BC) patients." | 7.80 | Plasma total homocysteine level in association with folate, pyridoxine, and cobalamin status among Iranian primary breast cancer patients. ( Atri, M; Foroutan-Ghaznavi, M; Mehdipour, P; Pirouzpanah, S; Taleban, FA, 2014) |
| "Prophylactic pyridoxine was given to 38 patients receiving capecitabine (alone or in combination with cyclophosphamide) for metastatic breast cancer and compared with historical data from 40 patients receiving capecitabine without pyridoxine in our clinic." | 7.76 | Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer. ( Fujita, T; Hayashi, H; Iwata, H; Kimura, M; Kondo, N; Toyama, T; Tsunoda, N; Tsuzuki, N; Yamashita, H; Yamashita, T; Yoshimoto, N, 2010) |
| "Pyridoxine, an activated form of vitamin B6 used to treat allergic dermatitis, may prevent capecitabine-associated hand-foot syndrome (HFS), although evidence of the benefit of prophylactic pyridoxine is lacking." | 5.27 | A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer. ( Hattori, M; Hayashi, T; Iwata, H; Kobayashi, N; Nakada, T; Saito, K; Sawaki, M; Toyama, T; Tsuneizumi, M; Yokota, I; Yoshimura, A, 2018) |
| "A total of 106 patients planned for palliative single-agent capecitabine (53 in each arm, 65%/35% colorectal/breast cancer) were randomised to receive either concomitant pyridoxine (50 mg po) or matching placebo three times daily." | 5.16 | A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications. ( Ahmad, A; Armstrong, G; Blesing, C; Bond, S; Bulusu, R; Corrie, PG; Daniel, F; Hardy, R; Hill, M; Lao-Sirieix, S; McAdam, K; Moody, AM; Osborne, M; Parashar, D; Wilson, CB; Wilson, G, 2012) |
| "Patients with histologically confirmed breast cancer or colorectal cancer receiving single agent capecitabine started at 2000 to 2500 mg/m(2) daily from day 1 to 14 every 3 weeks were randomly assigned to receive 200 mg or 400 mg daily of pyridoxine for PPE prophylaxis." | 5.14 | Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia. ( Chalermchai, T; Sriuranpong, V; Suwanrusme, H; Tantiphlachiva, K; Voravud, N, 2010) |
| " The objective of this study was to determine the associations between folate, cobalamin, and pyridoxine with fasting plasma tHcy concentration in breast cancer (BC) patients." | 3.80 | Plasma total homocysteine level in association with folate, pyridoxine, and cobalamin status among Iranian primary breast cancer patients. ( Atri, M; Foroutan-Ghaznavi, M; Mehdipour, P; Pirouzpanah, S; Taleban, FA, 2014) |
| "In vitro simultaneous combination of OHP and pyridoxine was studied in 6 CRC cell lines (HT29, Widr, SW480, HCT116, H630 and SW1116), in an ovarian cancer cell line (A2780) and its cisplatin-resistant subline (ADDP) and in an oestrogen-dependent breast cancer cell line (MCF-7)." | 3.77 | Pyridoxine to protect from oxaliplatin-induced neurotoxicity without compromising antitumour effect. ( Ackland, SP; Garg, MB, 2011) |
| "Prophylactic pyridoxine was given to 38 patients receiving capecitabine (alone or in combination with cyclophosphamide) for metastatic breast cancer and compared with historical data from 40 patients receiving capecitabine without pyridoxine in our clinic." | 3.76 | Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer. ( Fujita, T; Hayashi, H; Iwata, H; Kimura, M; Kondo, N; Toyama, T; Tsunoda, N; Tsuzuki, N; Yamashita, H; Yamashita, T; Yoshimoto, N, 2010) |
| " The toxicities, cumulative VCR dosage, and percentage of ideal dosage observed in 24 patients receiving pyridoxine have been compared to those observed in 88 patients who previously received VCR without pyridoxine in the same chemotherapy program." | 2.66 | Clinical trial of pyridoxine to reduce vincristine neurotoxicity. ( Atkins, JN; Callahan, RD; Cooper, MR; Grimm, RA; Hopkins, JO; Jackson, DV; McMahan, RA; Muss, HB; Paschold, EH; Pope, EK, 1986) |
| "Ninety-eight patients with metastatic breast cancer, heavily pretreated with other agents, were entered in a phase II trial of hexamethylmelamine (HEX)." | 2.65 | Phase II evaluation of hexamethylmelamine in advanced breast cancer: a Southwest Oncology Group study. ( Balcerzak, S; Fabian, CJ; Haut, A; Rasmussen, S; Smith, F; Stephens, R; Tranum, B, 1979) |
| "To investigate the incidence of breast cancer and prediagnostic serum levels of folate, B12, and pyridoxal 5'-phosphate (B6), we conducted a nested case-control study using resources from the Washington County (Maryland) serum bank." | 1.30 | A prospective study on folate, B12, and pyridoxal 5'-phosphate (B6) and breast cancer. ( Comstock, GW; Helzlsouer, KJ; Hoffman, SC; Nadeau, MR; Selhub, J; Wu, K, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (48.00) | 18.7374 |
| 1990's | 1 (4.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (40.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Machover, D | 1 |
| Goldschmidt, E | 1 |
| Almohamad, W | 1 |
| Castagné, V | 1 |
| Dairou, J | 1 |
| Desterke, C | 1 |
| Gomez, L | 1 |
| Gaston-Mathé, Y | 1 |
| Boucheix, C | 1 |
| Banerjee, S | 1 |
| Mukherjee, S | 1 |
| Bhattacharya, A | 1 |
| Basak, U | 1 |
| Chakraborty, S | 1 |
| Paul, S | 1 |
| Khan, P | 1 |
| Jana, K | 1 |
| Hazra, TK | 1 |
| Das, T | 1 |
| Egnell, M | 1 |
| Fassier, P | 1 |
| Lécuyer, L | 1 |
| Zelek, L | 1 |
| Vasson, MP | 1 |
| Hercberg, S | 1 |
| Latino-Martel, P | 1 |
| Galan, P | 1 |
| Deschasaux, M | 1 |
| Touvier, M | 1 |
| Toyama, T | 2 |
| Yoshimura, A | 1 |
| Hayashi, T | 1 |
| Kobayashi, N | 1 |
| Saito, K | 1 |
| Tsuneizumi, M | 1 |
| Sawaki, M | 1 |
| Hattori, M | 1 |
| Nakada, T | 1 |
| Yokota, I | 1 |
| Iwata, H | 2 |
| Pirouzpanah, S | 2 |
| Taleban, FA | 2 |
| Mehdipour, P | 2 |
| Atri, M | 2 |
| Hooshyareh-rad, A | 1 |
| Sabour, S | 1 |
| Ozkol, HU | 1 |
| Calka, O | 1 |
| Bulut, G | 1 |
| Foroutan-Ghaznavi, M | 1 |
| Yoshimoto, N | 1 |
| Yamashita, T | 1 |
| Fujita, T | 1 |
| Hayashi, H | 1 |
| Tsunoda, N | 1 |
| Kimura, M | 1 |
| Tsuzuki, N | 1 |
| Yamashita, H | 1 |
| Kondo, N | 1 |
| Chalermchai, T | 1 |
| Tantiphlachiva, K | 1 |
| Suwanrusme, H | 1 |
| Voravud, N | 1 |
| Sriuranpong, V | 1 |
| Garg, MB | 1 |
| Ackland, SP | 1 |
| Nakari, M | 1 |
| Kanouchi, H | 1 |
| Oka, T | 1 |
| Corrie, PG | 1 |
| Bulusu, R | 1 |
| Wilson, CB | 1 |
| Armstrong, G | 1 |
| Bond, S | 1 |
| Hardy, R | 1 |
| Lao-Sirieix, S | 1 |
| Parashar, D | 1 |
| Ahmad, A | 1 |
| Daniel, F | 1 |
| Hill, M | 1 |
| Wilson, G | 1 |
| Blesing, C | 1 |
| Moody, AM | 1 |
| McAdam, K | 1 |
| Osborne, M | 1 |
| Gart, JJ | 1 |
| Thomas, DG | 1 |
| DiSorbo, DM | 1 |
| Litwack, G | 1 |
| Bell, E | 1 |
| Wu, K | 1 |
| Helzlsouer, KJ | 1 |
| Comstock, GW | 1 |
| Hoffman, SC | 1 |
| Nadeau, MR | 1 |
| Selhub, J | 1 |
| Fabian, CJ | 1 |
| Rasmussen, S | 1 |
| Stephens, R | 1 |
| Haut, A | 1 |
| Smith, F | 1 |
| Balcerzak, S | 1 |
| Tranum, B | 1 |
| Bratseva, VL | 1 |
| Dickey, RP | 1 |
| Stone, SC | 1 |
| Fortmeyer, HP | 1 |
| Liebert, A | 1 |
| Busse, E | 1 |
| Ladner, HA | 1 |
| Salkeld, RM | 1 |
| Schrijver, J | 1 |
| Alexieva-Figusch, J | 1 |
| van Breederode, N | 1 |
| van Gilse, HA | 1 |
| Jackson, DV | 1 |
| Pope, EK | 1 |
| McMahan, RA | 1 |
| Cooper, MR | 1 |
| Atkins, JN | 1 |
| Callahan, RD | 1 |
| Paschold, EH | 1 |
| Grimm, RA | 1 |
| Hopkins, JO | 1 |
| Muss, HB | 1 |
| Rose, DP | 2 |
| McGinty, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Folic Acid Clinical Trial (FACT): Biomarker Subgroup Analysis[NCT03981029] | 51 participants (Actual) | Observational | 2011-12-19 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for pyridoxine and Breast Cancer
| Article | Year |
|---|---|
Drugs that affect the breast and lactation.
Topics: Androgens; Apomorphine; Barbiturates; Breast; Breast Neoplasms; Bromocriptine; Contraceptives, Oral, | 1975 |
Vitamin B6 status in cancer patients: effect of tumor site, irradiation, hormones and chemotherapy.
Topics: Breast Neoplasms; Estrogens; Female; Genital Neoplasms, Female; Humans; Neoplasms; Ovarian Neoplasms | 1988 |
Aspects of tryptophan metabolism in health and disease: a review.
Topics: Brain; Breast Neoplasms; Contraceptives, Oral; Depression; Endocrine System Diseases; Female; Glucoc | 1972 |
5 trials available for pyridoxine and Breast Cancer
| Article | Year |
|---|---|
A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer.
Topics: Aged; Breast Neoplasms; Capecitabine; Female; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Meta | 2018 |
Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Col | 2010 |
A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diseas | 2012 |
Phase II evaluation of hexamethylmelamine in advanced breast cancer: a Southwest Oncology Group study.
Topics: Aged; Altretamine; Breast Neoplasms; Drug Evaluation; Female; Humans; Middle Aged; Nausea; Nervous S | 1979 |
Clinical trial of pyridoxine to reduce vincristine neurotoxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1986 |
17 other studies available for pyridoxine and Breast Cancer
| Article | Year |
|---|---|
Pharmacologic modulation of 5-fluorouracil by folinic acid and pyridoxine for treatment of patients with advanced breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Fluorouracil; | 2022 |
Pyridoxine enhances chemo-responsiveness of breast cancer stem cells via redox reconditioning.
Topics: Breast Neoplasms; Doxorubicin; Female; Humans; Neoplastic Stem Cells; Oxidation-Reduction; Pyridoxin | 2020 |
B-Vitamin Intake from Diet and Supplements and Breast Cancer Risk in Middle-Aged Women: Results from the Prospective NutriNet-Santé Cohort.
Topics: Aged; Alcohol Drinking; Breast Neoplasms; Diet; Dietary Supplements; Exercise; Female; Follow-Up Stu | 2017 |
The biomarker-based validity of a food frequency questionnaire to assess the intake status of folate, pyridoxine and cobalamin among Iranian primary breast cancer patients.
Topics: Adult; Aged; Area Under Curve; Biomarkers; Body Mass Index; Breast Neoplasms; Diet; Female; Folic Ac | 2014 |
Chemotherapy-induced acral erythema with involvement of the face and neck: A case report.
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Dr | 2016 |
Plasma total homocysteine level in association with folate, pyridoxine, and cobalamin status among Iranian primary breast cancer patients.
Topics: Adult; Aged; Biomarkers; Body Mass Index; Breast Neoplasms; Fasting; Female; Folic Acid; Homocystein | 2014 |
Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deo | 2010 |
Pyridoxine to protect from oxaliplatin-induced neurotoxicity without compromising antitumour effect.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Colorectal Neoplasms; Cos | 2011 |
High dose of pyridoxine induces IGFBP-3 mRNA expression in MCF-7 cells and its induction is inhibited by the p53-specific inhibitor pifithrin-α.
Topics: Acetonitriles; Antineoplastic Agents; Apoptosis; Benzothiazoles; Breast Neoplasms; Cell Line, Tumor; | 2011 |
The performance of three approximate confidence limit methods for the odds ratio.
Topics: Abnormalities, Drug-Induced; Breast Neoplasms; Dicyclomine; Doxylamine; Drug Combinations; Epidemiol | 1982 |
Vitamin B6 kills hepatoma cells in culture.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Count; Cell Division; | 1982 |
The excretion of a vitamin B6 metabolite and the probabiliy of recurrence of early breast cancer.
Topics: 3-Hydroxyanthranilic Acid; Adult; Aged; Breast Neoplasms; Female; Humans; Isonicotinic Acids; Mastec | 1980 |
A prospective study on folate, B12, and pyridoxal 5'-phosphate (B6) and breast cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Case-Control Studies; Cohort Studies; | 1999 |
[Prophylaxis of complications caused by cytostatic drugs used in oncological patients].
Topics: Adolescent; Adult; Antineoplastic Agents; Breast Neoplasms; Child; Chlorides; Diazepam; Female; Foli | 1979 |
The effect of alpha-tocopherol on the growth of vitamin B6 responsive tumors in nude mice.
Topics: Animals; Breast Neoplasms; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pyridoxine; Transplan | 1989 |
Investigations on the nutritional status of advanced breast cancer patients. The influence of long-term treatment with megestrol acetate or tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Catecholamines; Female; Humans; Megestrol; Megestr | 1987 |
The influence of adrenocortical hormones and vitamins upon tryptophan metabolism in man.
Topics: Adrenocorticotropic Hormone; Adult; Benzoates; Breast Neoplasms; Female; Humans; Hydrocortisone; Kyn | 1968 |